Early Introduction of COMT Inhibitors at Low Levodopa Doses Improves Long-Term Motor Complications in Parkinson’s Disease: A sub-analysis of the REONPARK Study
Objective: This sub-analysis of the REONPARK study aims to identify predictive factors for the greater effectiveness of COMT inhibitors (COMTi) in alleviating motor complications in…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease
Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…Glucagon Like Peptide-1 (GLP-1) Receptor Agonists for Parkinson’s Disease: An Updated Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of GLP-1 receptor agonists in Parkinson's disease (PD) by adding new 2025 randomized controlled trial (RCT) data, and…Dopa Decarboxylase as a Biomarker for Parkinsons Disease and Its Relationship to L-Dopa Influence and Sample Size Estimates
Objective: To evaluate the relationship of CSF DDC with levodopa (L-DOPA) treatment and determine its feasibility as a biomarker in clinical trials based on sample…The Impact of Anodal transcranial Direct Current Stimulation on the Metabolomic Profiles of Cerebrospinal Fluid in Parkinson’s Disease
Objective: To explore the impact of anodal transcranial direct current stimulation (tDCS) on the cerebrospinal fluid (CSF) metabolomic profile of Parkinson's disease (PD). Background: Transcranial…Staging Disease Progression from Prodromal to Overt Stage of Alpha-synucleinopathies
Objective: To compute a disease progression model of the prodromal to overt synucleinopathy continuum, usable at single subject level. Background: Progression milestones to stage patients…Distinct Peripheral Immune Profiles of Parkinson’s Disease and Multiple System Atrophy
Objective: We aimed to compare peripheral blood mononuclear cell (PBMC) subsets between Parkinson’s disease (PD) and multiple system atrophy (MSA) to identify disease-specific immune signatures…Color Vision In Patients With Clinical Manifestations Of Rem Sleep Behavior Disorder
Objective: To evaluate the presence of changes in color vision in patients with REM sleep behavior disorder (RBD), Parkinson's disease (PD), and controls. Background: Visual…Plasma Lipids as Potential Biomarkers for Progression of Sleep Disturbances in Parkinson’s Disease
Objective: Determine if plasma lipid levels can serve as a surrogate biomarker of future onset of RBD symptoms or nighttime sleep burden in patients with…
- « Previous Page
- 1
- …
- 152
- 153
- 154
- 155
- 156
- …
- 181
- Next Page »